This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Missed Boat on New River

When you pick stocks for a living, whether it's as a portfolio manager, trader, analyst or columnist, you're bound to end up with both winners and losers over time. Every so often, a stock will end up burned in your memory as an example of perfect execution or everything going wrong.

With the buyout Tuesday of New River Pharmaceuticals (NRPH) by Shire (SHPGY), the New River story will leave me shaking my head in bewilderment for years to come, wondering where my analysis went wrong.

Over the past several months, I detailed the biotech company's sky-high valuation , its insider sales, its hiring of an executive that signaled expectations of a tough regulatory environment and most of all my belief that Vyvanse, its attention deficit hyperactivity disorder drug, will not be as successful as the Street expects.

But despite my being a nattering nabob of negativity, Shire found value to the tune of $2.6 billion in New River's business. Along with Vyvanse, Shire also obtains NRP290 -- a drug currently in phase II trials that is intended to be a safer and abuse-resistant alternative to acute pain medications such as Vicodin, OxyContin and Percocet -- and NRP409, a treatment for hypothyroidism that could enter clinical trials this year.

Price Points

The takeout premium is less than 10%, which leads me to believe that perhaps the parties involved in the negotiations realized the stock was fully valued. Biotech acquisitions have sported some large premiums over the past few months, including the 100% premium Merck (MRK - Get Report) paid for Sirna Therapeutics last year. Genentech (DNA) is in the process of acquiring Tanox (TNOX), for which it will pay a 47% premium.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $53.96 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%
GOOG $750.26 0.00%
TSLA $231.61 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs